Literature DB >> 30103065

Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change.

Lianne M Reus1, Everard Gb Vijverberg2, Betty M Tijms2, Mara Ten Kate2, Flora Gossink3, Welmoed A Krudop4, Marta Del Campo5, Charlotte E Teunissen5, Frederik Barkhof6, Wiesje M van der Flier2, Pieter Jelle Visser7, Annemiek Dols3, Yolande Al Pijnenburg2.   

Abstract

Behavioural variant frontotemporal dementia (bvFTD) is characterized by behavioural and social cognitive disturbances, while various psychiatric and neurodegenerative disorders may have similar clinical symptoms. Since neurodegenerative disorders are eventually progressive, whereas primary psychiatric disorders are not, this study aimed to investigate whether the change in clinical symptoms over time differed between groups and which biomarkers predicted rate of decline. Disease trajectories (median follow-up = 3 years) of frontal and stereotyped behaviour, general and frontal cognitive functioning, and social cognition were examined in bvFTD (n = 34), other neurodegenerative (n = 28) and primary psychiatric disorders (n = 43), all presenting with late-onset frontal lobe syndrome (45-75 years), using linear mixed models. To gain more insight in underlying pathological processes driving disease progression, we studied the association of baseline cerebrospinal fluid (CSF) (neurofilament light (NfL) and YKL-40 levels, phosphotau181 to total tau ratio) and neuroimaging markers with disease trajectories. Frontal behavioural symptoms (e.g., disinhibition, apathy) worsened over time in bvFTD, whereas they improved in psychiatric disorders and remained stable in other neurodegenerative disorders. General and frontal cognitive decline was observed in bvFTD and other neurodegenerative disorders, but not in psychiatric disorders. None of the groups showed change in stereotypy and social cognition. For all diagnostic groups, higher CSF NfL levels were associated with faster frontal cognitive decline. A modest association was observed between caudate volume and stereotyped behaviour. Tracking frontal behavioural symptoms and cognition has potential to distinguish bvFTD from other disorders. CSF NfL levels seem to be associated with decline in frontal cognitive functioning.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Behavioural variant frontotemporal dementia (bvFTD); Cerebrospinal fluid; Cortical thickness; Disease trajectories; Magnetic resonance imaging (MRI); Subcortical volumes

Mesh:

Year:  2018        PMID: 30103065     DOI: 10.1016/j.jpsychires.2018.07.014

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  4 in total

1.  Exploring the Relationship Between Deficits in Social Cognition and Neurodegenerative Dementia: A Systematic Review.

Authors:  Esther Setién-Suero; Nancy Murillo-García; Manuel Sevilla-Ramos; Georgelina Abreu-Fernández; Ana Pozueta; Rosa Ayesa-Arriola
Journal:  Front Aging Neurosci       Date:  2022-04-27       Impact factor: 5.702

Review 2.  The role of neurofilament light chain in frontotemporal dementia: a meta-analysis.

Authors:  Eleni Karantali; Dimitrios Kazis; Symela Chatzikonstantinou; Fivos Petridis; Ioannis Mavroudis
Journal:  Aging Clin Exp Res       Date:  2020-04-18       Impact factor: 3.636

Review 3.  What Do We Mean by Behavioral Disinhibition in Frontotemporal Dementia?

Authors:  Nahuel Magrath Guimet; Bruce L Miller; Ricardo F Allegri; Katherine P Rankin
Journal:  Front Neurol       Date:  2021-07-07       Impact factor: 4.003

4.  Caregiver burden in patients with behavioural variant frontotemporal dementia and non-fluent variant and semantic variant primary progressive aphasia.

Authors:  Michael Guger; Stefan Raschbacher; Lukas Kellermair; Milan R Vosko; Christian Eggers; Thomas Forstner; Karin Leitner; Alexandra Fuchs; Franz Fellner; Gerhard Ransmayr
Journal:  J Neural Transm (Vienna)       Date:  2021-07-19       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.